Sentinel Oncology enters agreement to develop new fragile X therapy
Sentinel Oncology announced today that it has entered an agreement with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies to support the clinical development of a first-in-class therapeutic with the potential to treat fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics.
“We are delighted to be collaborating with the MSRD team to advance SOL784 into clinical development” said Robert G Boyle, founder and CEO of Sentinel Oncology. “SOL784 targets the underlying disease biology of FXS and we are excited for the prospects of a drug which has the potential to provide real benefits to patients for whom there is an unmet medical need”.